Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2003
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/30/2003CA2106073C Composition for promoting tissue repair and regeneration
09/30/2003CA2102697C Pyrrolidine derivatives, preparation thereof and drugs containing same
09/25/2003WO2003079403A2 Oligo(ethylene glycol)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
09/25/2003WO2003079020A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
09/25/2003WO2003078959A2 Methods for shp1 mediated neuroprotection
09/25/2003WO2003078648A2 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078629A1 Constructs and methods for the regulation of gene expression
09/25/2003WO2003078614A2 Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants
09/25/2003WO2003078605A1 A selenium yeast product, a method of preparing a selenium yeast product and the use of the product for preparing food, a dietary supplement or a drug
09/25/2003WO2003078602A2 Methods of expressing non-endogenous g protein coupled receptors in cells
09/25/2003WO2003078601A2 Posh nucleic acids, polypeptides and related methods
09/25/2003WO2003078599A2 Method for generating primate trophoblasts
09/25/2003WO2003078598A2 Methods for using bag expression as a cell differentiation agent and marker
09/25/2003WO2003078594A2 Polynucleotide encoding a novel cysteine protease of the calpain superfamily, protease-42
09/25/2003WO2003078579A2 Compositions and methods for treating emphysema
09/25/2003WO2003078578A2 Modulation of the immune response through the manipulation of arginine levels
09/25/2003WO2003078574A2 Novel metabolic targets and markers
09/25/2003WO2003078572A2 Therapeutic polypeptides, nucleic acids encoding same and methods of use
09/25/2003WO2003078568A2 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
09/25/2003WO2003078467A1 Enhancement of iron chelation therapy
09/25/2003WO2003078466A1 Novel g protein-coupled recepotrs and genes thereof
09/25/2003WO2003078463A1 Repressor of skeletal muscle differentiation, nucleic acids coding therefor and the use thereof in diagnosis and therapy
09/25/2003WO2003078462A2 Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner
09/25/2003WO2003078460A1 Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
09/25/2003WO2003078457A1 MUTEINS OF THE C5a ANAPHYLATOXIN, NUCLEIC ACID MOLECULES ENCODING SUCH MUTEINS, AND PHARMACEUTICAL USES OF MUTEINS OF THE C5a ANAPHYLATOXIN
09/25/2003WO2003078456A2 Human diabetes-mediating proteins
09/25/2003WO2003078453A1 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
09/25/2003WO2003078448A1 Modulation of protein methylation and phosphoprotein phosphate
09/25/2003WO2003078383A1 Novel positively charged lipids and liposomes comprising the positively charged lipids
09/25/2003WO2003077954A1 Method for determining effect of a clostridial toxin upon a muscle
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077941A1 Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constituents, for externally treating open, in particular chronic wounds
09/25/2003WO2003077940A1 Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases
09/25/2003WO2003077939A1 Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
09/25/2003WO2003077938A1 Use of polypeptides of human origin for the treatment of microbial infectious diseases
09/25/2003WO2003077937A1 Pharmaceutical compositions comprising mannose binding lectin
09/25/2003WO2003077936A1 Cosmetic or pharmaceutical composition containing peptides
09/25/2003WO2003077935A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
09/25/2003WO2003077928A1 Peptide analogues and uses thereof
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077900A1 A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
09/25/2003WO2003077899A1 Anticancer composition
09/25/2003WO2003077882A2 Preparation of sterile stabilized nanodispersions
09/25/2003WO2003077872A2 Cell surface tropomyosin as a target of angiogenesis inhibition
09/25/2003WO2003077865A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077864A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077863A2 Method for overexpression of zwitterionic polysaccharides
09/25/2003WO2003077852A2 CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-β
09/25/2003WO2003077848A2 Jagged 2 inhibitors for inducing apoptosis
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077836A2 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
09/25/2003WO2003077834A2 Central airway administration for systemic delivery of therapeutics
09/25/2003WO2003077831A2 Compositions and methods for treating mdma-induced toxicity
09/25/2003WO2003077652A1 Method for treating diabetic ulcers
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003059277A3 Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
09/25/2003WO2003057240A3 Treatment and diagnosis of af4-dependant diseases
09/25/2003WO2003045434A3 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003042402A3 Agents that modulate immune cell activation and methods of use thereof
09/25/2003WO2003042246A3 Inhibitors of the notch signalling pathway for use in the treatment of cancer
09/25/2003WO2003041735A3 Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
09/25/2003WO2003040368A3 Pharmaceutical compositions of marine sponge microciona prolifera
09/25/2003WO2003040313A3 Il-21 antagonists
09/25/2003WO2003035682A3 Peptides and protins binding to glu-pro motidfs, therapeutical compositions containing them and their applications
09/25/2003WO2003033655A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
09/25/2003WO2003033519A3 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
09/25/2003WO2003031643A9 Methods for regulating co-stimulatory molecule expression with reactive oxygen
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003018064A3 Lipophilic drug compositions
09/25/2003WO2003014156A3 NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES
09/25/2003WO2003013594A3 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation
09/25/2003WO2003013577A3 Use of il-18 inhibitors in hypersensitivity disorders
09/25/2003WO2003013537A3 Irinotecan for treatment of cancer
09/25/2003WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1
09/25/2003WO2003012078A3 Dendritic cells and the uses thereof in screening cellular targets and potential drugs
09/25/2003WO2003008454A3 Glycoprotein vi fusion proteins
09/25/2003WO2003006993A3 Gel compositions
09/25/2003WO2003006489A3 Prodrugs of excitatory amino acids
09/25/2003WO2003006047A3 Methods for reducing immunogenicity of polypeptides
09/25/2003WO2003003988A3 Peptides which modulate blood coagulation and methods of use thereof
09/25/2003WO2003002114A3 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
09/25/2003WO2003000907A3 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation
09/25/2003WO2002100827A9 Method for increasing the survival of dopamine secreting cells
09/25/2003WO2002100324A3 Compositions and methods for the repair and construction of bone and other tissue
09/25/2003WO2002099116A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/25/2003WO2002085307A3 Glycopeptide antibiotics
09/25/2003WO2002085300A3 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
09/25/2003WO2002081705A3 Regulation of human gnat acetyltransferase-like protein
09/25/2003WO2002080847A3 Use of tumor necrosis factor inhibitors to treat cardiovascular disease
09/25/2003WO2002076482A3 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
09/25/2003WO2002069995A3 Use of trail and antiprogestins for treating cancer
09/25/2003WO2002068647A3 Proteins, polynucleotides encoding them and methods of using the same
09/25/2003WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002062819A3 Backbone cyclized radiolabelled somatostatin analogs
09/25/2003WO2002062368A3 Method of inducing a ctl response
09/25/2003WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
1 ... 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 ... 3163